Drug Search Results
More Filters [+]


Alternative Names: tiabendazole, bioguard, testo
Latest Update: 2024-03-27
Latest Update Note: Clinical Trial Update

Product Description

Thiabendazole is a broad spectrum anthelmintic agent used predominantly in treatment of intestinal pinworm and strongyloides infection, which recently has been replaced by better tolerated agents.  (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Thiabendazole)

Mechanisms of Action: Fumarate Reductase Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Intramuscular

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Australia | Brazil | Canada | India | Ireland | Italy | Malaysia | New Zealand | Portugal | Taiwan | United Arab Emirates | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Tiabendazole

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases



Trial Status


Primary Completion Date

Probability of Success

Recent News Events